Form D · Biotechnology

Aristea Therapeutics, Inc.

San Diego, CA · CIK 0001829049

Offering snapshot reported Aug 5, 2021 · SEC filing

Reported sold
$63.1M
Offering amount: $63.1M
Investors reported
15
Form D · investor count
Minimum accepted
$0
Reported outside-investor minimum
First sale
Oct 6, 2020
As reported in this filing

Fundraising history

Reported sold
Reported amount sold by Form D filing date$0$31.6M$63.1MOct 20, 2020: $39,620,984.00Oct 20, 2020Aug 5, 2021: $63,120,980.00Aug 5, 2021

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

  • Reported sold$39,620,984 → $63,120,980
  • Reported investors9 → 15

Filing history

Scroll to see all columns →

FiledFiling typeReported soldChange vs linked filingInvestorsSource
Aug 5, 2021Amendment$63,120,980$23,499,996vs Oct 20, 202015SEC filing
Oct 20, 2020Initial$39,620,984No comparison9SEC filing

Offering details

Securities
Equity
Exemptions
06b
Duration over one year
No
Business combination
No
Sales commissions
$0
Finders' fees
$0
Form D file number
021-378342
$60,499,994.09 new money; $2,620,986.30 conversion of notes

Source: Form D, filed Aug 5, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
NameReported role
Tiba Aynechi Director
Kenneth Harrison Director
Ciara Kennedy Director
James Mackay Director, Executive
Loretta Tse Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:
12770 High Bluff Drive Suite 380
San Diego, CA, 92130